Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
Assessment of safety and tolerability of drug combination and determine time on treatment, Overall survival (OS) and response rate with patient disease burden, and type of disease
Epistemonikos ID: a21405860d2160692629e1a30c2a2b48a227d07a
First added on: Jun 14, 2024